Stock Research for AMGN

AMGN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AMGN Stock Chart & Research Data

The AMGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AMGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AMGN Due diligence Resources & Stock Charts

The AMGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AMGN Detailed Price Forecast - CNN Money CNN View AMGN Detailed Summary - Google Finance
Yahoo View AMGN Detailed Summary - Yahoo! Finance Zacks View AMGN Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View AMGN Trends & Analysis - Trade-Ideas Barrons View AMGN Major Holders - Barrons
NASDAQ View AMGN Call Transcripts - NASDAQ Seeking View AMGN Breaking News & Analysis - Seeking Alpha
Spotlight View AMGN Annual Report - CompanySpotlight.com OTC Report View AMGN OTC Short Report - OTCShortReport.com
TradeKing View AMGN Fundamentals - TradeKing Charts View AMGN SEC Filings - Bar Chart
WSJ View Historical Prices for AMGN - The WSJ Morningstar View Performance/Total Return for AMGN - Morningstar
MarketWatch View the Analyst Estimates for AMGN - MarketWatch CNBC View the Earnings History for AMGN - CNBC
StockMarketWatch View the AMGN Earnings - StockMarketWatch MacroAxis View AMGN Buy or Sell Recommendations - MacroAxis
Bullish View the AMGN Bullish Patterns - American Bulls Short Pains View AMGN Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View AMGN Stock Mentions - StockTwits PennyStocks View AMGN Stock Mentions - PennyStockTweets
Twitter View AMGN Stock Mentions - Twitter Invest Hub View AMGN Investment Forum News - Investor Hub
Yahoo View AMGN Stock Mentions - Yahoo! Message Board Seeking Alpha View AMGN Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for AMGN - SECform4.com Insider Cow View Insider Transactions for AMGN - Insider Cow
CNBC View AMGN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AMGN - OTC Markets
Yahoo View Insider Transactions for AMGN - Yahoo! Finance NASDAQ View Institutional Holdings for AMGN - NASDAQ


Stock Charts

FinViz View AMGN Stock Insight & Charts - FinViz.com StockCharts View AMGN Investment Charts - StockCharts.com
BarChart View AMGN Stock Overview & Charts - BarChart Trading View View AMGN User Generated Charts - Trading View


Latest Financial News for AMGN

New Migraine Drugs Offer Hope to Sufferers
Posted on Monday May 21, 2018

Lisa DeLeonardo set a Google alert so she would know exactly when the first in a new class of migraine drugs was approved. It happened Thursday, when the U.S. Food and Drug Administration approved Amgen and Novartis’ application for erenumab, whose brand name is Aimovig. It’s an injectable drug touted as the first treatment designed specifically to prevent migraines, and is expected to be available to patients within a week for an annual price of $6,900.


Regional cycling fans show up in numbers for Amgen Tour (PHOTOS)
Posted on Monday May 21, 2018

Northern California showed itself to be an accommodating and receptive host for the 13th annual Amgen Tour of California.


FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis
Posted on Monday May 21, 2018

THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. This approval is based on data from a Phase 3 study which showed patients on glucocorticoid therapy who received Prolia had greater gains in bone mineral density (BMD) compared to those who received active comparator (risedronate).


Company News For May 21, 2018
Posted on Monday May 21, 2018

Companies in the news are: PYPL,AMGN,TTD,CBS


Enter a stock symbol to view the stock details.